Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Net Cash Flow (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Net Cash Flow for 16 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 253.08% to $36.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100.3 million through Dec 2025, up 98.44% year-over-year, with the annual reading at $100.3 million for FY2025, 98.44% up from the prior year.
  • Net Cash Flow hit $36.1 million in Q4 2025 for Ligand Pharmaceuticals, down from $69.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $69.3 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
  • Historically, Net Cash Flow has averaged $6.3 million across 5 years, with a median of $129500.0 in 2021.
  • Biggest five-year swings in Net Cash Flow: surged 1146.58% in 2022 and later plummeted 637.71% in 2023.
  • Year by year, Net Cash Flow stood at -$3.9 million in 2021, then soared by 1146.58% to $40.9 million in 2022, then tumbled by 92.43% to $3.1 million in 2023, then skyrocketed by 230.62% to $10.2 million in 2024, then skyrocketed by 253.08% to $36.1 million in 2025.
  • Business Quant data shows Net Cash Flow for LGNDZ at $36.1 million in Q4 2025, $69.3 million in Q3 2025, and $20.1 million in Q2 2025.